Pharmaceutical Company

Platani, Greece

Pharmaceutical Company

Platani, Greece
SEARCH FILTERS
Time filter
Source Type

In this report, the United States Pharmaceutical market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: The West Southwest The Middle Atlantic New England The South The Midwest with sales (volume), revenue (value), market share and growth rate of Pharmaceutical in these regions, from 2012 to 2022 (forecast). For more information or any query mail at sales@wiseguyreports.com United States Pharmaceutical market competition by top manufacturers/players, with Pharmaceutical sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including FLOWSERVE Wilo Pentair KSB Ebara HCP ITT Argal Grundfos PharmaProduct Manufacturing Pharmaceutical Enterprises Sanofi-Aventis On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into Precision Treatment Pump Solutions Other On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Pharmaceutical for each application, including Pharmaceutical Company Research Institute Other If you have any special requirements, please let us know and we will offer you the report as you want. United States Pharmaceutical Market Report 2017 1 Pharmaceutical Overview 1.1 Product Overview and Scope of Pharmaceutical 1.2 Classification of Pharmaceutical by Product Category 1.2.1 United States Pharmaceutical Market Size (Sales Volume) Comparison by Type (2012-2022) 1.2.2 United States Pharmaceutical Market Size (Sales Volume) Market Share by Type (Product Category) in 2016 1.2.3 Precision Treatment 1.2.4 Pump Solutions 1.2.5 Other 1.3 United States Pharmaceutical Market by Application/End Users 1.3.1 United States Pharmaceutical Market Size (Consumption) and Market Share Comparison by Application (2012-2022) 1.3.2 Pharmaceutical Company 1.3.3 Research Institute 1.3.4 Other 1.4 United States Pharmaceutical Market by Region 1.4.1 United States Pharmaceutical Market Size (Value) Comparison by Region (2012-2022) 1.4.2 The West Pharmaceutical Status and Prospect (2012-2022) 1.4.3 Southwest Pharmaceutical Status and Prospect (2012-2022) 1.4.4 The Middle Atlantic Pharmaceutical Status and Prospect (2012-2022) 1.4.5 New England Pharmaceutical Status and Prospect (2012-2022) 1.4.6 The South Pharmaceutical Status and Prospect (2012-2022) 1.4.7 The Midwest Pharmaceutical Status and Prospect (2012-2022) 1.5 United States Market Size (Value and Volume) of Pharmaceutical (2012-2022) 1.5.1 United States Pharmaceutical Sales and Growth Rate (2012-2022) 1.5.2 United States Pharmaceutical Revenue and Growth Rate (2012-2022) 2 United States Pharmaceutical Market Competition by Players/Suppliers 2.1 United States Pharmaceutical Sales and Market Share of Key Players/Suppliers (2012-2017) 2.2 United States Pharmaceutical Revenue and Share by Players/Suppliers (2012-2017) 2.3 United States Pharmaceutical Average Price by Players/Suppliers (2012-2017) 2.4 United States Pharmaceutical Market Competitive Situation and Trends 2.4.1 United States Pharmaceutical Market Concentration Rate 2.4.2 United States Pharmaceutical Market Share of Top 3 and Top 5 Players/Suppliers 2.4.3 Mergers & Acquisitions, Expansion in United States Market 2.5 United States Players/Suppliers Pharmaceutical Manufacturing Base Distribution, Sales Area, Product Type 6 United States Pharmaceutical Players/Suppliers Profiles and Sales Data 6.1 FLOWSERVE 6.1.1 Company Basic Information, Manufacturing Base and Competitors 6.1.2 Pharmaceutical Product Category, Application and Specification 6.1.2.1 Product A 6.1.2.2 Product B 6.1.3 FLOWSERVE Pharmaceutical Sales, Revenue, Price and Gross Margin (2012-2017) 6.1.4 Main Business/Business Overview 6.2 Wilo 6.2.2 Pharmaceutical Product Category, Application and Specification 6.2.2.1 Product A 6.2.2.2 Product B 6.2.3 Wilo Pharmaceutical Sales, Revenue, Price and Gross Margin (2012-2017) 6.2.4 Main Business/Business Overview 6.3 Pentair 6.3.2 Pharmaceutical Product Category, Application and Specification 6.3.2.1 Product A 6.3.2.2 Product B 6.3.3 Pentair Pharmaceutical Sales, Revenue, Price and Gross Margin (2012-2017) 6.3.4 Main Business/Business Overview 6.4 KSB 6.4.2 Pharmaceutical Product Category, Application and Specification 6.4.2.1 Product A 6.4.2.2 Product B 6.4.3 KSB Pharmaceutical Sales, Revenue, Price and Gross Margin (2012-2017) 6.4.4 Main Business/Business Overview 6.5 Ebara 6.5.2 Pharmaceutical Product Category, Application and Specification 6.5.2.1 Product A 6.5.2.2 Product B 6.5.3 Ebara Pharmaceutical Sales, Revenue, Price and Gross Margin (2012-2017) 6.5.4 Main Business/Business Overview 6.6 HCP 6.6.2 Pharmaceutical Product Category, Application and Specification 6.6.2.1 Product A 6.6.2.2 Product B 6.6.3 HCP Pharmaceutical Sales, Revenue, Price and Gross Margin (2012-2017) 6.6.4 Main Business/Business Overview 6.7 ITT 6.7.2 Pharmaceutical Product Category, Application and Specification 6.7.2.1 Product A 6.7.2.2 Product B 6.7.3 ITT Pharmaceutical Sales, Revenue, Price and Gross Margin (2012-2017) 6.7.4 Main Business/Business Overview 6.8 Argal 6.8.2 Pharmaceutical Product Category, Application and Specification 6.8.2.1 Product A 6.8.2.2 Product B 6.8.3 Argal Pharmaceutical Sales, Revenue, Price and Gross Margin (2012-2017) 6.8.4 Main Business/Business Overview 6.9 Grundfos 6.9.2 Pharmaceutical Product Category, Application and Specification 6.9.2.1 Product A 6.9.2.2 Product B 6.9.3 Grundfos Pharmaceutical Sales, Revenue, Price and Gross Margin (2012-2017) 6.9.4 Main Business/Business Overview 6.10 PharmaProduct Manufacturing 6.10.2 Pharmaceutical Product Category, Application and Specification 6.10.2.1 Product A 6.10.2.2 Product B 6.10.3 PharmaProduct Manufacturing Pharmaceutical Sales, Revenue, Price and Gross Margin (2012-2017) 6.10.4 Main Business/Business Overview 6.11 Pharmaceutical Enterprises 6.12 Sanofi-Aventis For more information or any query mail at sales@wiseguyreports.com ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of rmaket research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com


— The Global Pharmaceutical Market Research Report 2017is a professional and in-depth study on the current state of the Pharmaceutical industry. In a word, This report studies Pharmaceutical in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer. Key companies included in this research are FLOWSERVE, Wilo, Pentair, KSB, Ebara, HCP, ITT, Argal, Grundfos, PharmaProduct Manufacturing, Pharmaceutical Enterprises and Sanofi-Aventis. Market Segment by Region, this report splits Global into several key Region, with sales, revenue, market share and growth rate of Pharmaceutical in these regions, from 2011 to 2022 (forecast), like North America, Europe, China, Japan, Southeast Asia and India. Firstly, Pharmaceutical On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into Precision Treatment, Pump Solutions and Other. On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Pharmaceutical for each application, including, Pharmaceutical Company, Research Institute and Other. 7 Global Pharmaceutical Manufacturers Profiles/Analysis 7.1 FLOWSERVE 7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.1.2 Pharmaceutical Product Category, Application and Specification 7.1.2.1 Product A 7.1.2.2 Product B 7.1.3 FLOWSERVE Pharmaceutical Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.1.4 Main Business/Business Overview 7.2 Wilo 7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.2.2 Pharmaceutical Product Category, Application and Specification 7.2.2.1 Product A 7.2.2.2 Product B 7.2.3 Wilo Pharmaceutical Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.2.4 Main Business/Business Overview 7.3 Pentair 7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.3.2 Pharmaceutical Product Category, Application and Specification 7.3.2.1 Product A 7.3.2.2 Product B 7.3.3 Pentair Pharmaceutical Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.3.4 Main Business/Business Overview Figure Picture of Pharmaceutical Figure Global Pharmaceutical Production (K Units) and CAGR (%) Comparison by Types (Product Category) (2012-2022) Figure Global Pharmaceutical Production Market Share by Types (Product Category) in 2016 Figure Product Picture of Precision Treatment Table Major Manufacturers of Precision Treatment Figure Product Picture of Pump Solutions Table Major Manufacturers of Pump Solutions Figure Product Picture of Other Table Major Manufacturers of Other Figure Global Pharmaceutical Consumption (K Units) by Applications (2012-2022) Figure Global Pharmaceutical Consumption Market Share by Applications in 2016 Figure Pharmaceutical Company Examples Figure Research Institute Examples Figure Other Examples Figure Global Pharmaceutical Market Size (Million USD), Comparison (K Units) and CAGR (%) by Regions (2012-2022) Figure North America Pharmaceutical Revenue (Million USD) and Growth Rate (2012-2022) Figure Europe Pharmaceutical Revenue (Million USD) and Growth Rate (2012-2022) Figure China Pharmaceutical Revenue (Million USD) and Growth Rate (2012-2022) Figure Japan Pharmaceutical Revenue (Million USD) and Growth Rate (2012-2022) Figure Southeast Asia Pharmaceutical Revenue (Million USD) and Growth Rate (2012-2022) Figure India Pharmaceutical Revenue (Million USD) and Growth Rate (2012-2022) Figure Global Pharmaceutical Revenue (Million USD) Status and Outlook (2012-2022) Figure Global Pharmaceutical Capacity, Production (K Units) Status and Outlook (2012-2022) Figure Global Pharmaceutical Major Players Product Capacity (K Units) (2012-2017) Table Global Pharmaceutical Capacity (K Units) of Key Manufacturers (2012-2017) Table Global Pharmaceutical Capacity Market Share of Key Manufacturers (2012-2017) Figure Global Pharmaceutical Capacity (K Units) of Key Manufacturers in 2016 Figure Global Pharmaceutical Capacity (K Units) of Key Manufacturers in 2017 Figure Global Pharmaceutical Major Players Product Production (K Units) (2012-2017) Table Global Pharmaceutical Production (K Units) of Key Manufacturers (2012-2017) Table Global Pharmaceutical Production Share by Manufacturers (2012-2017) Figure 2016 Pharmaceutical Production Share by Manufacturers Figure 2017 Pharmaceutical Production Share by Manufacturers Figure Global Pharmaceutical Major Players Product Revenue (Million USD) (2012-2017) Table Global Pharmaceutical Revenue (Million USD) by Manufacturers (2012-2017) Table Global Pharmaceutical Revenue Share by Manufacturers (2012-2017) Table 2016 Global Pharmaceutical Revenue Share by Manufacturers Table 2017 Global Pharmaceutical Revenue Share by Manufacturers Table Global Market Pharmaceutical Average Price (USD/Unit) of Key Manufacturers (2012-2017) Figure Global Market Pharmaceutical Average Price (USD/Unit) of Key Manufacturers in 2016 Table Manufacturers Pharmaceutical Manufacturing Base Distribution and Sales Area For more information, please visit http://www.reportsweb.com/global-pharmaceutical-market-research-report-2017


SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (La Jolla) today announced that results of the ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) Phase 3 study of LJPC-501 (angiotensin II) have been published online by The New England Journal of Medicine (NEJM). The article, entitled “Angiotensin II for the Treatment of Vasodilatory Shock,” also will be published in the May 25, 2017 print issue of NEJM. “There is a major need for new treatment options for critically ill patients who do not adequately respond to available vasopressors,” stated Rinaldo Bellomo, M.D., Professor of Intensive Care Medicine at University of Melbourne and Director of Intensive Care Research at Austin Health. “In ATHOS-3, angiotensin II was shown to raise blood pressure with no increase in overall adverse events as compared to placebo in this highly treatment-resistant patient population. The effect of angiotensin II resulted in reduced use of other vasopressors. If approved, angiotensin II, in combination with other vasopressors, may allow clinicians to leverage all three major physiologic systems that regulate blood pressure.” The analysis of the primary efficacy endpoint of ATHOS-3, defined as the percentage of patients achieving a mean arterial pressure (MAP) ≥ 75 mmHg or a 10 mmHg increase from baseline MAP at 3 hours following the initiation of study treatment without an increase in standard-of-care vasopressors, was statistically significant: 23.4% of the 158 placebo-treated patients achieved the pre-specified blood pressure response, compared to 69.9% of the 163 angiotensin II-treated patients (p<0.001). In addition, a trend toward longer survival was observed for angiotensin II-treated patients (22% reduction in mortality risk through day 28; hazard ratio=0.78 [CI: 0.57, 1.07; p=0.12]). In this critically ill patient population, 91.8% of placebo-treated patients experienced at least one adverse event, compared to 87.1% of angiotensin II-treated patients, and 21.5% of placebo-treated patients discontinued treatment due to an adverse event, compared to 14.1% of angiotensin II-treated patients. The NEJM article can be found here and its Supplementary Appendix can be found here. The ATHOS-3 study was a multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical study of LJPC-501 in patients with catecholamine resistant hypotension (CRH), which is a severe form of vasodilatory shock. A total of 344 patients were randomized across nine countries, 321 of whom received study treatment and are included in the primary analysis. Patients were randomized 1:1 to receive either LJPC-501 or placebo on a background of standard-of-care vasopressors selected by the investigators. Randomized patients received their assigned treatment via continuous intravenous infusion. The primary efficacy endpoint was the percentage of patients achieving a mean arterial pressure (MAP) ≥ 75 mmHg or a 10 mmHg increase from baseline MAP at 3 hours following the initiation of study treatment without an increase in standard-of-care vasopressors. The study was conducted under a Special Protocol Assessment (SPA) agreed to with the U.S. Food and Drug Administration (FDA) in 2015. The SPA stipulates that a study of this size and design could provide sufficient safety and efficacy data and an adequate evaluation of the risk/benefit to the patients to support FDA review and consideration for marketing approval. La Jolla reported positive top-line results in February 2017. LJPC-501 is La Jolla’s proprietary formulation of synthetic human angiotensin II. Angiotensin II, the major bioactive component of the renin-angiotensin system, serves as one of the body’s central regulators of blood pressure. LJPC-501 is being developed for the treatment of patients with CRH. LJPC-501 is the first synthetic human angiotensin II product candidate to be tested in a Phase 3 study. Catecholamine resistant hypotension (CRH) is a life-threatening syndrome in patients with vasodilatory (also known as distributive) shock (dangerously low blood pressure with adequate cardiac function) who cannot achieve target mean arterial pressure (MAP) despite adequate fluid resuscitation and treatment with currently available vasopressors (catecholamines and/or vasopressin). There are approximately 500,000 distributive shock cases in the United States per year, an estimated 200,000 of which develop CRH. More than 50% of CRH patients die within 30 days. La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla's proprietary formulation of synthetic human angiotensin II for the potential treatment of catecholamine resistant hypotension. LJPC-401 is La Jolla's proprietary formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is La Jolla's next-generation gentamicin derivative program that is focused on the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. For more information on La Jolla, please visit www.ljpc.com. This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or the company’s future results of operations. These statements are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors, that may cause actual results to be materially different from those anticipated by the forward-looking statements. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the company’s filings with the U.S. Securities and Exchange Commission (SEC), all of which are available free of charge on the SEC’s web site www.sec.gov. These risks include, but are not limited to, risks relating to: the timing of the planned NDA submission for LJPC-501 and prospects for approval of LJPC-501 by the FDA and the other regulatory authorities; risks relating to the scope of product labels (if approved) and potential market sizes, as well as the broader commercial opportunity; the anticipated timing for regulatory actions; and the success of future development activities; potential indications for which the company’s product candidates may be developed. The company expressly disclaims any intent to update any forward-looking statements to reflect the outcome of the consequent events.


News Article | May 17, 2017
Site: marketersmedia.com

LOS ANGELES, CA / ACCESSWIRE / May 17, 2017 / Pediapharm Inc. (TSX-V: PDP), Canada's Leading Pediatric Pharmaceutical Company, today announced that it will be presenting at the 7th annual LD Micro Invitational on Tuesday, June 6 at 3:30PM PST / 6:30PM EST. Sylvain Chretien, CEO of Pediapharm Inc., will be giving the presentation and meeting with investors. Pediapharm's mission is to bring to the Canadian market the latest innovative pediatric products from around the world with the objective to improve the health and the well-being of children in Canada. It has entered into numerous commercial agreements with partners from around the world, including North America and Europe. The Company's innovative product portfolio includes NYDA®, a breakthrough treatment for head lice; Rupall™, an innovative new allergy medication with a unique dual mode of action; Otixal™, the first and only antibiotic and steroid combination ear drop available in single, sterile, preservative-free and unit-dose packaging; and Cuvposa™, for severe drooling, which is currently under review with Health Canada. "This year, not only do we have a record number of companies making their LD Micro debuts, but a record number of companies presenting for the first time in their company's history," stated Chris Lahiji, President of LD Micro. "LD has established itself as the one venue that brings the most influential players from all segments of the market under one roof." The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 180 companies in the small / micro-cap space. Pediapharm's mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. It has entered into numerous commercial agreements with partners from Canada and other countries around the world. The Company's innovative product portfolio includes NYDA®, a breakthrough treatment for head lice; Rupall™, an innovative new allergy medication with a unique mode of action; Otixal™, the first and only antibiotic and steroid combination ear drop available in single, sterile, preservative-free and unit-dose packaging; and Cuvposa™, for severe drooling, which is under review with Health Canada. LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe. For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information. LOS ANGELES, CA / ACCESSWIRE / May 17, 2017 / Pediapharm Inc. (TSX-V: PDP), Canada's Leading Pediatric Pharmaceutical Company, today announced that it will be presenting at the 7th annual LD Micro Invitational on Tuesday, June 6 at 3:30PM PST / 6:30PM EST. Sylvain Chretien, CEO of Pediapharm Inc., will be giving the presentation and meeting with investors. Pediapharm's mission is to bring to the Canadian market the latest innovative pediatric products from around the world with the objective to improve the health and the well-being of children in Canada. It has entered into numerous commercial agreements with partners from around the world, including North America and Europe. The Company's innovative product portfolio includes NYDA®, a breakthrough treatment for head lice; Rupall™, an innovative new allergy medication with a unique dual mode of action; Otixal™, the first and only antibiotic and steroid combination ear drop available in single, sterile, preservative-free and unit-dose packaging; and Cuvposa™, for severe drooling, which is currently under review with Health Canada. "This year, not only do we have a record number of companies making their LD Micro debuts, but a record number of companies presenting for the first time in their company's history," stated Chris Lahiji, President of LD Micro. "LD has established itself as the one venue that brings the most influential players from all segments of the market under one roof." The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 180 companies in the small / micro-cap space. Pediapharm's mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. It has entered into numerous commercial agreements with partners from Canada and other countries around the world. The Company's innovative product portfolio includes NYDA®, a breakthrough treatment for head lice; Rupall™, an innovative new allergy medication with a unique mode of action; Otixal™, the first and only antibiotic and steroid combination ear drop available in single, sterile, preservative-free and unit-dose packaging; and Cuvposa™, for severe drooling, which is under review with Health Canada. LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe. For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.


News Article | May 17, 2017
Site: www.accesswire.com

LOS ANGELES, CA / ACCESSWIRE / May 17, 2017 / Pediapharm Inc. (TSX-V: PDP), Canada's Leading Pediatric Pharmaceutical Company, today announced that it will be presenting at the 7th annual LD Micro Invitational on Tuesday, June 6 at 3:30PM PST / 6:30PM EST. Sylvain Chretien, CEO of Pediapharm Inc., will be giving the presentation and meeting with investors. Pediapharm's mission is to bring to the Canadian market the latest innovative pediatric products from around the world with the objective to improve the health and the well-being of children in Canada. It has entered into numerous commercial agreements with partners from around the world, including North America and Europe. The Company's innovative product portfolio includes NYDA®, a breakthrough treatment for head lice; Rupall™, an innovative new allergy medication with a unique dual mode of action; Otixal™, the first and only antibiotic and steroid combination ear drop available in single, sterile, preservative-free and unit-dose packaging; and Cuvposa™, for severe drooling, which is currently under review with Health Canada. "This year, not only do we have a record number of companies making their LD Micro debuts, but a record number of companies presenting for the first time in their company's history," stated Chris Lahiji, President of LD Micro. "LD has established itself as the one venue that brings the most influential players from all segments of the market under one roof." The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 180 companies in the small / micro-cap space. Pediapharm's mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. It has entered into numerous commercial agreements with partners from Canada and other countries around the world. The Company's innovative product portfolio includes NYDA®, a breakthrough treatment for head lice; Rupall™, an innovative new allergy medication with a unique mode of action; Otixal™, the first and only antibiotic and steroid combination ear drop available in single, sterile, preservative-free and unit-dose packaging; and Cuvposa™, for severe drooling, which is under review with Health Canada. LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe. For those interested in attending, please contact David Scher at [email protected] or visit www.ldmicro.com for more information.


News Article | May 23, 2017
Site: www.marketwired.com

Revenue Improved 362% and Gross Profit Improved 415% compared to the three months ended March 31, 2016 CHICAGO, IL--(Marketwired - May 23, 2017) - Cosmos Holdings, Inc. ("the Company") ( : COSM), an international pharmaceutical company, announced financial results for the quarter ended March 31, 2017. For the quarter ended March 31, 2017, versus the quarter ended March 31, 2016, Cosmos Holdings' revenue improved 362% to $4.1 million from $1.1 million on the strength of its SkyPharm SA subsidiary, which obtained the necessary capital during 2016 and 2017 in order to develop, expand and organically grow its operations. Of note, revenue improved sequentially 27%, from $3.2 million in the 2016 fourth quarter to $4.1 million in the 2017 first quarter due to the organic growth in Sky Pharm SA and the acquisition of the UK subsidiary Decahedron Ltd. Additionally, gross profit increased 415% to $363,692 in the first quarter of 2017 from $87,676 in the first quarter of 2016. During the first quarter of 2017 Cosmos Holdings completed the acquisition of the UK based pharmaceutical company Decahedron Ltd. With this acquisition, Cosmos expands its geographic market improving its access to additional vendors and customers moving closer to its goal of becoming an International Pharmaceutical Company. Cosmos Holdings was successful in securing $2.6 million of institutional capital as of the first quarter of 2017. The company also entered into an agreement for an additional 2,750,000 EUR of capital through its subsidiary Decahedron in the form of a trade facility in April 2017. Moreover, in May 12, 2017 the company entered into another trade finance agreement and received institutional financing of 2,000,000 EUR through its subsidiary Skypharm SA. Cosmos Holdings CEO Gregory Siokas commented, "In the first quarter of 2017 we successfully completed the strategic acquisition of Decahedron Ltd, expanding our reach to the UK market. Currently we are working hard to accelerate the growth of our subsidiaries and moving forward with the acquisition of carefully targeted companies that will add value to the Company and its shareholders. During 2017 we are planning to complete additional acquisitions, continue to enter into new markets, and expand our product lines to include generic drugs and cosmetics products." About Cosmos Holdings, Inc. Cosmos Holdings Inc. is a pharmaceutical company focused on identifying, acquiring, developing, and commercializing medicines to improve patients' lives and outcomes. The Company has a trans-European network of more than 60 clients and vendors in Germany, the United Kingdom, Ireland, Denmark, Poland, Netherlands, and Greece. Its warehouse and distribution center is located in Thessaloniki, Greece and is GDP & ISO 9001:2008 certified. More information is available at www.cosmosholdingsinc.com. Cosmos Holdings, Inc. takes no responsibility for updating the information contained in this press release following the date hereof to reflect events or circumstances occurring after the date hereof or the occurrence of unanticipated events or for any changes or modifications made to this press release or the information contained herein by any third-parties, including, but not limited to, any wire or internet services. FORWARD LOOKING STATEMENTS Except for historical information, this news release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve unknown risks, and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Important factors that might cause such differences are discussed in the Company's filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results could differ materially from those anticipated in these forward-looking statements, if new information becomes available in the future.


News Article | May 24, 2017
Site: www.marketwired.com

CHICAGO, IL--(Marketwired - May 24, 2017) - In the news release, "Cosmos Holdings, Inc. Announces first Quarter 2017 Results," issued yesterday, May 23, by Cosmos Holdings ( : COSM), we are advised by the company that the subhead should read "Revenue Improved 262% and Gross Profit Improved 315% compared to the three months ended March 31, 2016." The "revenue improved" and "gross profit" percentages in the second paragraph were also updated. Complete corrected text follows. Revenue Improved 262% and Gross Profit Improved 315% compared to the three months ended March 31, 2016 CHICAGO, IL -- May 23, 2017 -- Cosmos Holdings, Inc. ("the Company") ( : COSM), an international pharmaceutical company, announced financial results for the quarter ended March 31, 2017. For the quarter ended March 31, 2017, versus the quarter ended March 31, 2016, Cosmos Holdings' revenue improved 262% to $4.1 million from $1.1 million on the strength of its SkyPharm SA subsidiary, which obtained the necessary capital during 2016 and 2017 in order to develop, expand and organically grow its operations. Of note, revenue improved sequentially 27%, from $3.2 million in the 2016 fourth quarter to $4.1 million in the 2017 first quarter due to the organic growth in Sky Pharm SA and the acquisition of the UK subsidiary Decahedron Ltd. Additionally, gross profit increased 315% to $363,692 in the first quarter of 2017 from $87,676 in the first quarter of 2016. During the first quarter of 2017 Cosmos Holdings completed the acquisition of the UK based pharmaceutical company Decahedron Ltd. With this acquisition, Cosmos expands its geographic market improving its access to additional vendors and customers moving closer to its goal of becoming an International Pharmaceutical Company. Cosmos Holdings was successful in securing $2.6 million of institutional capital as of the first quarter of 2017. The company also entered into an agreement for an additional 2,750,000 EUR of capital through its subsidiary Decahedron in the form of a trade facility in April 2017. Moreover, in May 12, 2017 the company entered into another trade finance agreement and received institutional financing of 2,000,000 EUR through its subsidiary Skypharm SA. Cosmos Holdings CEO Gregory Siokas commented, "In the first quarter of 2017 we successfully completed the strategic acquisition of Decahedron Ltd, expanding our reach to the UK market. Currently we are working hard to accelerate the growth of our subsidiaries and moving forward with the acquisition of carefully targeted companies that will add value to the Company and its shareholders. During 2017 we are planning to complete additional acquisitions, continue to enter into new markets, and expand our product lines to include generic drugs and cosmetics products." About Cosmos Holdings, Inc. Cosmos Holdings Inc. is a pharmaceutical company focused on identifying, acquiring, developing, and commercializing medicines to improve patients' lives and outcomes. The Company has a trans-European network of more than 60 clients and vendors in Germany, the United Kingdom, Ireland, Denmark, Poland, Netherlands, and Greece. Its warehouse and distribution center is located in Thessaloniki, Greece and is GDP & ISO 9001:2008 certified. More information is available at www.cosmosholdingsinc.com. Cosmos Holdings, Inc. takes no responsibility for updating the information contained in this press release following the date hereof to reflect events or circumstances occurring after the date hereof or the occurrence of unanticipated events or for any changes or modifications made to this press release or the information contained herein by any third-parties, including, but not limited to, any wire or internet services. FORWARD LOOKING STATEMENTS Except for historical information, this news release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve unknown risks, and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Important factors that might cause such differences are discussed in the Company's filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results could differ materially from those anticipated in these forward-looking statements, if new information becomes available in the future.


— Pipeline report on Sickle Cell Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sickle Cell Disease (Hematological Disorders). The complete is analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Browse the 54 Tables and 11 Figures, 36 Company Profiles, Spread across 191 Pages Report Available at http://www.reportsnreports.com/reports/992906-sickle-cell-disease-pipeline-review-h1-2017.html . Sickle Cell Disease - Companies Involved in Therapeutics Development - Acceleron Pharma Inc, Addex Therapeutics Ltd, Addmedica SAS, Advinus Therapeutics Ltd, Alnylam Pharmaceuticals Inc, Angiocrine Bioscience Inc, ArQule Inc, Bio Products Laboratory Ltd, Bioverativ Inc, bluebird bio Inc, Bristol-Myers Squibb Company, Calimmune Inc, CRISPR Therapeutics, CSL Ltd 35,Editas Medicine Inc, Errant Gene Therapeutics LLC, Gamida Cell Ltd, Genethon SA, Gilead Sciences Inc, Global Blood Therapeutics Inc, Incyte Corp, Johnson & Johnson, La Jolla Pharmaceutical Company, MaxCyte Inc, Merck & Co Inc, Modus Therapeutics Holding AB, Morphogenesis Inc, NKT Therapeutics Inc, Novartis AG, Orphagen Pharmaceuticals Inc, Pfizer Inc, Prolong Pharmaceuticals LLC, Protagonist Therapeutics Inc, ReveraGen BioPharma Inc, Sancilio & Company Inc, Sangamo Therapeutics Inc. Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant. The Sickle Cell Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 5, 9, 27, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 2 molecules, respectively. Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=992906 Sickle Cell Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope • The pipeline guide provides a snapshot of the global therapeutic landscape of Sickle Cell Disease (Hematological Disorders). • The pipeline guide reviews pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Sickle Cell Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Sickle Cell Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/992906-sickle-cell-disease-pipeline-review-h1-2017.html

Loading Pharmaceutical Company collaborators
Loading Pharmaceutical Company collaborators